ArticleNature communications2023
Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 85 citations in OpenAlex.
- The perinecrotic niche of glioblastoma drives tumor-associated macrophage polarization and immunosuppression via podoplanin-mediated CLEC5A activation.The Journal of clinical investigation · 2026Article
- oHSV-1-modulated mVirology journal · 2026Article
- Astrocyte-associated immunosuppressive programs in brain tumors: a STAT3-centered perspective.Cancer metastasis reviews · 2026Review
- Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment.Cellular & molecular immunology · 2026Review
- Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook.Clinical and translational medicine · 2026Review
- Development and validation of a preoperative glycolipid metabolism-based nomogram for predicting postoperative recurrence in primary glioma: a retrospective cohort study.Lipids in health and disease · 2026Article
- Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer.Cancer biology & medicine · 2026Review
- Review
- Article
- Cholesterol Metabolism-related Characteristics Predict Therapeutic Response and Survival in Esophageal Cancer.Journal of advanced research · 2026Article
- cRGD-Functionalized macrophage extracellular vesicles loaded with GSK2033 enhance T cell antitumor immunity in GBM by disrupting the LXR/ABCA1-Mediated Myelin lipid transfer axis.Journal of nanobiotechnology · 2026Article
- Multiomics identifies a cholesterol-TFEB-PLD3-TLR9 axis driving immunosuppressive tumor-associated macrophage polarization in esophageal squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.Nature cancer · 2026Review
- Glia-derived VCAM1 promotes glioma progression.Frontiers in oncology · 2026Article
- Activated astrocytes drive the accumulation of apolipoprotein E at the brain tumor edge.Brain tumor pathology · 2026Article
- APOs as promising prognostic biomarkers: correlation with tumor-infiltrating leukocytes in endometrial cancer.Frontiers in immunology · 2026Article
- Dendritic cells in cancer immunotherapy: functional barriers, reprogramming strategies and translational challenges.Frontiers in immunology · 2026Review
- The immunosuppressive tumor microenvironment in glioblastoma.Frontiers in immunology · 2026Review
- Engineered nanomedicine remodels the postoperative cavity microenvironment to suppress glioblastoma recurrence.Theranostics · 2026Review
- Altered lipid profile in uterine leiomyoma: a focus on apolipoprotein A1 reduction and machine learning-based predictive modeling.Frontiers in medicine · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The codependency of cholesterol metabolism sustains the malignant progression of glioblastoma (GBM) and effective therapeutics remain scarce. In orthotopic GBM models in male mice, we identify that codependent cholesterol metabolism in tumors induces phagocytic dysfunction in monocyte-derived tumor-associated macrophages (TAMs), resulting in disease progression. Manipulating cholesterol efflux with apolipoprotein A1 (ApoA1), a cholesterol reverse transporter, restores TAM phagocytosis and reactivates TAM-T cell antitumor immunity. Cholesterol metabolomics analysis of in vivo-sorted TAMs further reveals that ApoA1 mediates lipid-related metabolic remodeling and lowers 7-ketocholesterol levels, which directly inhibits tumor necrosis factor signaling in TAMs through mitochondrial translation inhibition. An ApoA1-armed oncolytic adenovirus is also developed, which restores antitumor immunity and elicits long-term tumor-specific immune surveillance. Our findings provide insight into the mechanisms by which cholesterol metabolism impairs antitumor immunity in GBM and offer an immunometabolic approach to target cholesterol disturbances in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.